Clinical Trial of TQB2922 for Injection in Patients With Advanced Cancers

Inclusion Criteria:

• Subjects voluntarily join this study, sign the informed consent form, and have goodcompliance；

• Age: 18-75 years; Eastern Cooperative Oncology Group (ECOG) score: 0-1 ; Expectedsurvival of more than 3 months；

• Histologically or cytologically diagnosed with advanced cancers;

• Subjects with advanced malignancies who have failed standard therapy or lackeffective treatment;

• Major organs are functioning well;

• Female and male subjects of childbearing potential should agree to practicecontraception during the study and until 6 months after the completion of the study.

Exclusion Criteria:

• Current concomitant or ever presented with other malignancies within 2 years priorto the first dose;

• Unresolved toxicity of Grade 1 or above according to CTCAE due to any prioranti-tumor therapy;

• Significant surgical treatment, biopsy, or significant traumatic injury within 28days prior to the first dose;

• Long-term unhealed wounds or fractures

• Cerebrovascular accident (including transient ischemic attack, intracerebralhemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolismwithin 6 months prior to the first dose;

• A history of psychotropic drug abuse and cannot be abstained, or have a mentaldisorder;

• Subjects with any severe and/or uncontrolled disease;

• History of live attenuated vaccination within 2 weeks prior to the first dose orplanned live attenuated vaccination during the study;

• Previous history of unexplained severe allergies, hypersensitivity to monoclonalantibodies or exogenous human immunoglobulins, or hypersensitivity to TQB2922 forinjection or its excipients;

• According to the judgment of the investigator, there are concomitant diseases thatseriously endanger the safety of the patients or affect the completion of the study,or subjects who are considered to be unsuitable for enrollment for other reasons.